SAM
MCRB icon

Simplify Asset Management’s Seres Therapeutics MCRB Stock Holding History

Simplify Asset Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-27,531
Closed -$1.31M – 134
2023
Q3 		$1.31M Hold
27,531
– – 0.15% 68
2023
Q2 		$2.64M Hold
27,531
– – 0.35% 39
2023
Q1 		$3.12M Buy
+27,531
New +$2.98M 0.45% 26

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Simplify Asset Management's MCRB Position: Q4 2023 in Review

Simplify Asset Management sold out of Seres Therapeutics (MCRB) in Q4 2023, closing a stake of 27,531 shares — an estimated $1.31M sold.

Simplify Asset Management first reported a position in MCRB in Q1 2023 and held it in 3 quarters. The position peaked at $3.12M in Q1 2023. 102 funds tracked by Wall St. Rank hold MCRB as of Q4 2023.

  • Simplify Asset Management reported no remaining Seres Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Simplify Asset Management sold 27,531 Seres Therapeutics shares in Q4 2023, an estimated $1.31M.
  • Simplify Asset Management first reported a position in Seres Therapeutics in Q1 2023 and held it in 3 quarters.
  • Simplify Asset Management's Seres Therapeutics position peaked at $3.12M in Q1 2023.
  • 102 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2023.

Based on Simplify Asset Management's 13F filing for Q4 2023, filed 12 Feb 2024.